Sales & Marketing
Tariffs, pharma, and patients: A Q&A with Orr Inbar
The threat of tariffs has loomed over countries and industries alike …
21480 items found
News
IPO plan evaporates as private equity firm buys Stada
Reports last week that German pharma group Stada was planning an …
News
ESC: Real-world study gives Wegovy edge over Lilly rival
With competition in the GLP-1 category increasingly cutthroat, Novo …
News
Sanofi breaks new ground for BTK drugs with ITP approval
Sanofi's BTK inhibitor Wayrilz has become the first drug in the class …
News
ESC: 'Landmark' study backs AZ's baxdrostat for hypertension
The full data from AstraZeneca's phase 3 BaxHTN trial of baxdrostat …
Partner Content
Partner Content
News
Dose-at-home Leqembi for Alzheimer's cleared in US
Eisai and Biogen have won FDA approval for a subcutaneous injection …
R&D
No longer the little fish: How Europe is holding its own through US uncertainty
It goes without saying that we are living in uncertain times, yet, …
News
Trump appoints HHS deputy O'Neill to lead CDC
The current director of the CDC is challenging her dismissal, but …
News
UK adds chickenpox to childhood vaccination schedule
The UK will start offering free vaccination against chickenpox to …
News
Outlook blindsided as FDA blocks wet AMD drug once again
Shares in Outlook Therapeutics lost more than half their value after …
News
Novo reels in Replicate for new cardiometabolic drugs
California biotech Replicate Biosciences will receive up to $550 …
Sales & Marketing
Tariffs, pharma, and patients: A Q&A with Orr Inbar
In order to discuss the current unsettled landscape, and just how tariffs might affect patients, pharmaphorum spoke with Orr Inbar of QuantHealth.
Market Access
Sponsored
Bridging research and clinical guidelines – interactive stra...
Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
Market Access
12 questions with: Daniel Kohlstaedt
Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.
R&D
Life Sciences Industry Report - Biologics and Generics
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
R&D
Increasing trial efficiency: Adityo Prakash talks small data...
Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.
Oncology
Life Sciences Industry Report - Oncology
Developments in the oncology space in 2024 brought hope to both industry and patients.
Partner Content
Partner Content
The Antifibrotic Drug Development Summit returns this Novemb...
Harness cross-fibrotic insights and make new connections this November in Boston
R&D
Partner Content
Revolutionising Clinical Trials: Evolution Summit 2025 Retur...
Marcus Evans is proud to announce the Evolution Summit September 2025, an exclusive, invitation-only event bringing together leading clinical trial executives, innovative suppliers
